Intellectual property, pharmaceutical MNEs and the developing world

Pervez N. Ghauri; P. M. Rao

doi:10.1016/j.jwb.2008.05.008

Intellectual property, pharmaceutical MNEs and the developing world

Pervez N. Ghauri, P. M. Rao

King's Business School

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

The paper examines the structure of pharmaceutical R&D funding, spillovers and public-private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving incentives for the multinational enterprise (MNE) innovation and making patented drugs accessible to the poor countries at affordable prices. The paper argues for a vastly expanded size and scope of public-academic-nonprofit funding of R&D, whose results could become a global public good. Finally, the paper suggests that the international business scholars further explore the implications of the strong private-public-academic linkages found in the pharmaceutical research combined with the trends towards open innovation and economic development. (C) 2008 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	206 - 215
Number of pages	10
Journal	JOURNAL OF WORLD BUSINESS
Volume	44
Issue number	2
DOIs	https://doi.org/10.1016/j.jwb.2008.05.008
Publication status	Published - Apr 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jwb.2008.05.008

Cite this

@article{b65ebc1eabe449fb95972279e8df9ddd,

title = "Intellectual property, pharmaceutical MNEs and the developing world",

abstract = "The paper examines the structure of pharmaceutical R&D funding, spillovers and public-private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving incentives for the multinational enterprise (MNE) innovation and making patented drugs accessible to the poor countries at affordable prices. The paper argues for a vastly expanded size and scope of public-academic-nonprofit funding of R&D, whose results could become a global public good. Finally, the paper suggests that the international business scholars further explore the implications of the strong private-public-academic linkages found in the pharmaceutical research combined with the trends towards open innovation and economic development. (C) 2008 Elsevier Inc. All rights reserved.",

author = "Ghauri, {Pervez N.} and Rao, {P. M.}",

year = "2009",

month = apr,

doi = "10.1016/j.jwb.2008.05.008",

language = "English",

volume = "44",

pages = "206 -- 215",

journal = "JOURNAL OF WORLD BUSINESS",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Intellectual property, pharmaceutical MNEs and the developing world

AU - Ghauri, Pervez N.

AU - Rao, P. M.

PY - 2009/4

Y1 - 2009/4

N2 - The paper examines the structure of pharmaceutical R&D funding, spillovers and public-private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving incentives for the multinational enterprise (MNE) innovation and making patented drugs accessible to the poor countries at affordable prices. The paper argues for a vastly expanded size and scope of public-academic-nonprofit funding of R&D, whose results could become a global public good. Finally, the paper suggests that the international business scholars further explore the implications of the strong private-public-academic linkages found in the pharmaceutical research combined with the trends towards open innovation and economic development. (C) 2008 Elsevier Inc. All rights reserved.

AB - The paper examines the structure of pharmaceutical R&D funding, spillovers and public-private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving incentives for the multinational enterprise (MNE) innovation and making patented drugs accessible to the poor countries at affordable prices. The paper argues for a vastly expanded size and scope of public-academic-nonprofit funding of R&D, whose results could become a global public good. Finally, the paper suggests that the international business scholars further explore the implications of the strong private-public-academic linkages found in the pharmaceutical research combined with the trends towards open innovation and economic development. (C) 2008 Elsevier Inc. All rights reserved.

U2 - 10.1016/j.jwb.2008.05.008

DO - 10.1016/j.jwb.2008.05.008

M3 - Article

VL - 44

SP - 206

EP - 215

JO - JOURNAL OF WORLD BUSINESS

JF - JOURNAL OF WORLD BUSINESS

IS - 2

ER -

Intellectual property, pharmaceutical MNEs and the developing world

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this